Tebentafusp (tebe) in a real-world cohort of 72 French metastatic uveal melanoma (UM) patients (pts).
Sophie Piperno‐Neumann(Institut Curie), Manuel Rodrigues(Inserm), Vincent Servois(Université Paris Sciences et Lettres), Marc Pracht(Canadian Partnership Against Cancer), N. Litrowski(Université de Rouen Normandie), Léah Mailly-Giacchetti(Inserm), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Pierre Combe(Hôpital Européen Georges-Pompidou), Jean Christophe Théry(Centre Henri Becquerel), Mathilde Saint‐Ghislain(Centre Oscar Lambret), Leanne de Koning(Université Paris Sciences et Lettres), Toulsie Ramtohul(Université Paris Sciences et Lettres), Hélène Martin(Centre National de la Recherche Scientifique), Agathe Garcia(Institut Curie)
Cited by 1
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k